TK13thesis_killerthesis_killer
Biotech/Synbio Safety Event
Prior probability
15.0%
Current probability
15.0%
evolves via intake + LBP
Conviction
—
Signal quality
—
Resolution
pending
Window
2026-01-01 – 2030-12-31
Edges in / out
0 / 30
Tickers exposed
0
Prediction text
Major clinical trial death, synbio containment breach, or AI-generated pathogen scare triggers FDA slowdown; biotech/synbio investment freezes 12-24 months.
Predictor calibration
Not assigned
This node has no predictor assigned. Default κ=0.5 applies to any intake evidence about it.
Reference class
Not linked
This node isn't linked to a reference class. The Bayesian update applies without outside-view blending.
Probability over time
0 prob_history rows
No probability history yet.
Milestone chain
Pre-event signals (upstream prereqs + window checkpoints) → resolution event → downstream cascades. Status/dates update from linked nodes; re-derive nightly via scripts/ops/derive_milestones.py.
No milestone chain derived yet. Run scripts/ops/derive_milestones.py to populate from prereq edges + window checkpoints.
What if this resolves?
Clamp this prediction TRUE or FALSE and run a counterfactual Gibbs sample. Surfaces the predictions whose marginals shift most under that assumption.
(live posterior: 15%)
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Every probability update with full Bayesian provenance — chronological, latest first
No probability history yet. The first evidence will arrive via /api/intake or the daily milestone sweep / weekly LBP run.
Network propagation neighbors
Top edges sorted by latest LBP cross-impact
Top incoming (parents)
Edges that influence THIS node's belief
No incoming edges.
Top outgoing (children)
Predictions THIS node influences
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| killer | 235_030 Ray Kurzweil predicts Longevity Escape Velocity (LEV) by 203 — Ray Kurzweil | 39.2% | 0.050 | 0.750 | +0.253 |
| killer | 233_015 Infinite longevity is coming for this generation of kids. — Peter Diamandis | 37.6% | 0.050 | 0.650 | +0.184 |
| killer | 245_003 Colossal's $10B valuation is massively undervalued — Ben Lamm | 29.8% | 0.050 | 0.500 | +0.134 |
| killer | 245_012 UAE's Biovault is a nine-figure initiative for both Colossal — Ben Lamm | 66.8% | 0.050 | 0.920 | +0.121 |
| killer | 235_027 Longevity VC market expected to grow from $8.5B in 2024 to $ — Peter Diamandis | 46.5% | 0.050 | 0.650 | +0.095 |
Prerequisites (0)
Predictions that must hit first
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| No prerequisites | ||||
Dependents (30)
Predictions enabled by this
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| killer | 245_012 | UAE's Biovault is a nine-figure initiative for both Colossal and the UAE | Biotech/Longevity | — |
| killer | 245_025 | Colossal gene editing efficiency has risen from 15% industry / 40% internal to 90% at hundreds of edits | Biotech/Longevity | — |
| killer | 235_030 | Ray Kurzweil predicts Longevity Escape Velocity (LEV) by 2033. | Biotech/Longevity | — |
| killer | 245_011 | Colossal is spinning out a dozen companies each with massive potential | Biotech/Longevity | — |
| killer | 233_015 | Infinite longevity is coming for this generation of kids. | Biotech/Longevity | — |
| killer | 235_027 | Longevity VC market expected to grow from $8.5B in 2024 to $12-18B in 2026. | Biotech/Longevity | — |
| killer | 235_028 | Longevity market will grow from $5 trillion to $8 trillion in next four years. | Biotech/Longevity | — |
| killer | 238_011 | Frontier AI labs will generate trillions of dollars in new revenue from breakthroughs (longevity, superconductors, fusion) | AI | — |
| killer | 239_006 | AI will solve everything including longevity | AI | — |
| killer | 245_005 | Countries will become customers to preserve endangered species via Colossal | Biotech/Longevity | — |
| killer | 235_029 | Big pharma companies will transition into longevity business in next 3 years. | Biotech/Longevity | — |
| killer | IND_010 | Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... | Biotech/Longevity | — |
| killer | 245_033 | Colossal will work to reintroduce all de-extincted species back into their environments | Biotech/Longevity | — |
| killer | 245_039 | Colossal has not yet started work on dinosaurs, corals, dragons or Pokemon | Biotech/Longevity | — |
| killer | 245_041 | Colossal will build a living lab in UAE in addition to Biovault | Biotech/Longevity | — |
| killer | 245_045 | Colossal considers Colossal platform core will stay focused on biodiversity and de-extinction | Biotech/Longevity | — |
| killer | 245_003 | Colossal's $10B valuation is massively undervalued | Markets/Stocks | — |
| killer | 245_007 | Colossal will bring back the woolly mammoth | Biotech/Longevity | — |
| killer | 245_014 | Colossal has major announcements coming this year with a local government on productionizing cloning of endangered species | Biotech/Longevity | — |
| killer | 245_024 | Colossal gene editing will reach thousands of edits (up from current hundreds) | Biotech/Longevity | — |
| killer | 245_027 | Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 | Biotech/Longevity | — |
| killer | 245_036 | Colossal will continue seeding and spinning out new companies from scientific discoveries | Biotech/Longevity | — |
| killer | 245_015 | Colossal could theoretically create Pikachu (engineer novel designer organisms) | Biotech/Longevity | — |
| killer | 239_031 | Ben Lamb / Colossal could engineer a Pikachu-like creature | Biotech/Longevity | — |
| killer | 245_006 | Colossal will productionize species development via biobanking, synthetic biology, automation, AI, computer vision and artificial wombs | Biotech/Longevity | — |
| killer | 245_026 | Colossal editing tech will be applicable to human healthcare (spun out/licensed) | Biotech/Longevity | — |
| killer | 245_029 | IVF will be transformed by Colossal's hydrogel/microfluidics embryo tech and new grading scale | Biotech/Longevity | — |
| killer | IND_020 | Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving... | Biotech/Longevity | — |
| killer | AUT_027 | Integration of AI with advanced bio-sensing, quantum computing, and genomics enables humanity to achieve 'Longevity Escape Velocity' — tipping point where medical technology extends human lifespan faster than time passes; continuous biological surveill... | Biotech/Longevity | — |
| killer | IND_022 | AGI arrives before 2029 (Turing test); true Singularity (ASI) occurs in 2040s — total human-machine convergence enabling: mental transfer from brain to brain, integration of nanobots into human bloodstream for perfect biological health maintenance, ach... | Biotech/Longevity | — |
Linked documents (10)
Auto-generated by cosine similarity from Polymarket / Manifold / EDGAR / GDELT
| Sim | Source | Title | Market prob | Polarity | Reviewed | Published |
|---|---|---|---|---|---|---|
| 0.647 | arxiv | BioRefusalAudit: Auditing Biosecurity Refusal Depth Using General and Domain-Fine-Tuned Sparse Autoencoders | — | mentions | pending | 2026-05-28 |
| 0.595 | edgar_8k | CRISPR Therapeutics AG (CRSP) (CIK 0001674416) | — | mentions | pending | 2026-06-04 |
| 0.592 | fda | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | — | mentions | pending | 2026-04-17 |
| 0.589 | polymarket | Ebola case in the US by June 30? | 23% | mentions | pending | 2026-05-15 |
| 0.586 | arxiv | Text Knows What, Tables Know When: Clinical Timeline Reconstruction via Retrieval-Augmented Multimodal Alignment | — | mentions | pending | 2026-05-14 |
| 0.585 | fda | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | — | mentions | pending | 2026-04-17 |
| 0.585 | fda | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | — | mentions | pending | 2026-05-20 |
| 0.583 | fda | FDA ANDA220499: ANDA220499 ((unspecified)) — ALEMBIC PHARMACEUTICALS LIMITED | — | mentions | pending | 2026-05-13 |
| 0.579 | edgar_8k | Twist Bioscience Corp (TWST) (CIK 0001581280) | — | mentions | pending | 2026-05-04 |
| 0.577 | fda | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | — | mentions | pending | 2026-04-15 |
Raw metadata
From Thesis_Timeline_v1.0_FINAL workbook
{
"mechanism": "Major clinical trial death, synbio containment breach, or AI-generated pathogen scare triggers FDA slowdown; biotech/synbio investment freezes 12-24 months.",
"time_window": "2026-2030",
"scenario_name": "Biotech/Synbio Safety Event",
"affected_domains": "Biotech (28), AI (2), Markets (1)",
"hedge_candidates": [
"Long big pharma",
"short synbio small caps"
],
"monitoring_cadence": "Quarterly — biotech trial failure tracking; FDA AdCom outcomes",
"affected_pred_count": 31,
"early_warning_signals": "Clinical trial halt patterns; FDA advisory committee dissent; synbio lab breach reports",
"countervailing_factors": "Robust biosafety framework deploys; AI-driven drug discovery wins consume headlines",
"sample_affected_pred_ids": [
"230_024",
"233_015",
"235_027",
"235_028",
"235_029",
"235_030",
"238_011",
"239_006",
"239_031",
"245_003",
"..."
],
"tickers_flipping_adverse_to_benef": [
"Big pharma (LLY",
"NVO",
"PFE)",
"defensive healthcare (JNJ",
"UNH)",
"CRISPR ADCs"
],
"tickers_flipping_benef_to_adverse": [
"Synbio private + public (GINK",
"DNA ex-delist",
"BEAM",
"CRSP",
"NTLA)"
]
}